OCGN vs. SLDB, SOPH, CRBU, TNYA, JSPR, MGTX, AURA, TCRX, AVXL, and ADPT
Should you be buying Ocugen stock or one of its competitors? The main competitors of Ocugen include Solid Biosciences (SLDB), SOPHiA GENETICS (SOPH), Caribou Biosciences (CRBU), Tenaya Therapeutics (TNYA), Jasper Therapeutics (JSPR), MeiraGTx (MGTX), Aura Biosciences (AURA), TScan Therapeutics (TCRX), Anavex Life Sciences (AVXL), and Adaptive Biotechnologies (ADPT). These companies are all part of the "biological products, except diagnostic" industry.
Solid Biosciences (NASDAQ:SLDB) and Ocugen (NASDAQ:OCGN) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, media sentiment, dividends, institutional ownership, analyst recommendations, valuation, earnings, risk and community ranking.
In the previous week, Ocugen had 6 more articles in the media than Solid Biosciences. MarketBeat recorded 8 mentions for Ocugen and 2 mentions for Solid Biosciences. Ocugen's average media sentiment score of 0.44 beat Solid Biosciences' score of 0.41 indicating that Solid Biosciences is being referred to more favorably in the media.
Ocugen's return on equity of -62.11% beat Solid Biosciences' return on equity.
Solid Biosciences has a beta of 2.02, suggesting that its stock price is 102% more volatile than the S&P 500. Comparatively, Ocugen has a beta of 3.49, suggesting that its stock price is 249% more volatile than the S&P 500.
Solid Biosciences presently has a consensus target price of $18.25, suggesting a potential upside of 75.65%. Ocugen has a consensus target price of $4.67, suggesting a potential upside of 193.50%. Given Solid Biosciences' higher probable upside, analysts clearly believe Ocugen is more favorable than Solid Biosciences.
Solid Biosciences received 151 more outperform votes than Ocugen when rated by MarketBeat users. However, 68.49% of users gave Ocugen an outperform vote while only 67.47% of users gave Solid Biosciences an outperform vote.
81.5% of Solid Biosciences shares are owned by institutional investors. Comparatively, 10.3% of Ocugen shares are owned by institutional investors. 19.3% of Solid Biosciences shares are owned by company insiders. Comparatively, 3.5% of Ocugen shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Ocugen has lower revenue, but higher earnings than Solid Biosciences. Ocugen is trading at a lower price-to-earnings ratio than Solid Biosciences, indicating that it is currently the more affordable of the two stocks.
Summary
Solid Biosciences beats Ocugen on 9 of the 16 factors compared between the two stocks.
Get Ocugen News Delivered to You Automatically
Sign up to receive the latest news and ratings for OCGN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding OCGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
